Stocks
Terns Pharmaceuticals IncTERN
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing small-molecule therapies for obesity and metabolic disorders. Its lead candidate, TERN-601, is an oral GLP-1 receptor agonist in Phase 1 trials, positioning it in the competitive weight-loss drug market. Investors track Terns for its potential to offer an oral alternative to injectable GLP-1 treatments.
Congressional Interest in Terns Pharmaceuticals Inc (TERN)
1 member of Congress has disclosed 1 trade in Terns Pharmaceuticals Inc (TERN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading TERN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-06-27 | MICHAEL T. MCCAUL | sell | $1K-$15K |